Treatment of Sjogren's syndrome with essential fatty acids, pyridoxine and vitamin C.
Sjogren's Syndrome (S.S.) is characterized clinically by oral and ocular dryness and immunologically by its frequent association with autoimmune diseases and the presence of various circulating autoantibodies. Evidence has been presented suggesting that S.S. may be due to a relative deficiency of PGE1 and that elevating PGE1 levels may reduce oral and ocular dryness. In an attempt to increase PGE1 levels, precursors of PGE1 including di-homo-gamma linolenic acid, ascorbic acid and pyridoxine in the form of dietary supplements were administered to 10 patients with S.S. for 10 weeks. There was no significant improvement in any of the patients during the treatment period compared to assessments done pre and post treatment. Measurements of oral and ocular dryness of 6 patients on prostaglandin synthetase inhibiting anti-inflammatory medications were similar to the 4 patients on no medication.
D001205:Ascorbic Acid / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001241:Aspirin / Q000627:therapeutic use; D005228:Fatty Acids, Essential / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D011736:Pyridoxine / Q000627:therapeutic use*; D012859:Sjogren's Syndrome / Q000188:drug therapy*
D005228:Fatty Acids, Essential; D001219:Aspartate Aminotransferases; D011736:Pyridoxine; D001205:Ascorbic Acid; D001241:Aspirin; D007213:Indomethacin